Why Edwards Lifesciences Corporation (EW) stock moved
No significant move on Nov 18, 2026 (−0.2%, close-to-close). Latest notable session: Nov 9, 2026.
Why Edwards Lifesciences Corporation (EW) rose 2.5% on November 9, 2026
Edwards Lifesciences Corporation (EW) rose 2.5% on November 9, 2026, closing at $104.71 versus $102.14 the prior session (close-to-close, from daily closes). Driven by continued positive momentum from its strong Q3 2026 results ($1.72B sales, $0.80 adjusted EPS beat), raised full-year guidance, and a wave of analyst price-target upgrades from UBS, JPMorgan, Citigroup, and Truist Financial. Volume was normal at 1.09x the historical average for this time of day. Source: defenseworld.net.
Edwards Lifesciences rose 2.14% to $104.33, driven by continued positive momentum from its strong Q3 2026 results ($1.72B sales, $0.80 adjusted EPS beat), raised full-year guidance, and a wave of analyst price-target upgrades from UBS, JPMorgan, Citigroup, and Truist Financial. Volume was normal at 1.09x the historical average for this time of day.
What to watch next: EW earnings scheduled for 2027-02-09 (consensus estimate: $0.66 EPS); monitor any further clinical trial readouts or approval announcements for TAVR/TMTT therapies.
Earlier sessions that moved EW
- +4.4%Announced positive clinical trial results.
- −2.6%We checked news, earnings, analyst updates, filings, and corporate actions — no company-specific catalyst was found.
- +2.9%Ahead of Q3 earnings (Seeking Alpha).
- +4.1%Driven by expanded Medicare coverage for TAVR (transcatheter aortic valve replacement) procedures to asymptomatic patients and management presentations at the Deutsche Bank 2026 Healthcare Summit.
- −2.8%As broader market weakness—driven by rising Treasury yields and macroeconomic headwinds—pressured the stock alongside valuation concerns and recent insider selling activity (web_catalyst).
- −3.5%Market data indicates routine day-to-day fluctuations and normal trading behavior within recent ranges, per web search synthesis.
Edwards Lifesciences Corporation (EW) shares fell 0.4% to $104.82 as of November 19, 2026, a slight decline from the prior close of $105.23. BestStocks flagged the session as a major change for EW. Below, we break down what changed for EW, why it matters for investors, how the stock reacted, and the catalysts on the calendar.
EW fell 0.4% to $104.81
EW fell 0.4% in its latest session, moving from $105.23 to $104.82.
What it means for Edwards Lifesciences Corporation investors
For Edwards Lifesciences Corporation investors, the recent signals add up to a bearish shift. On the constructive side: Positive price momentum. Weighing against that: Negative session, down 0.4%; Edwards Lifesciences declined 2.34% to $87.80 in early intraday trading with no major negative catalyst identified. Wall Street's consensus price target sits at $108.70, implying +3.7% upside from $104.82. Over the past 90 days analysts logged 1 upgrade and 0 downgrades. BestStocks rates the overall signal quality weak (27/100). With earnings roughly 82 days out, the next report is the most likely near-term test of the move.
EW price reaction
EW last traded at $104.82, down $0.42 (-0.39%) from the previous close of $105.23. The session traded on 0.0× average volume (below avg), so participation was unremarkable. Over the past month the stock has ranged between $87.22 and $107.15, and it currently sits about 88% of the way up that band.
Bullish and bearish analyst opinions on Edwards Lifesciences Corporation (EW)
The consensus analyst price target on Edwards Lifesciences Corporation (EW) is $108.70, 3.7% above the recent $104.82. Over the past 90 days analysts logged 1 upgrade, 14 maintains, and 0 downgrades. Here is how the bullish and bearish cases on EW line up.
The bullish case
- Wall Street's consensus price target of $108.70 implies +3.7% upside from $104.82.
- The Street's most bullish target is $120.00 (+14.5%).
- 1 analyst upgrade in the past 90 days, most recently Truist Securities to Buy (2026-11-04).
- Positive price momentum.
The bearish case
- The most bearish analyst target is $100.00 (-4.6%).
- Negative session, down 0.4%.
- Edwards Lifesciences declined 2.34% to $87.80 in early intraday trading with no major negative catalyst identified.
Weighing both sides, BestStocks' composite read of recent signals is bearish, as the bull-versus-bear meter above shows. This is an educational summary of the bull and bear case, not investment advice.
Analyst price targets and ratings are FMP consensus figures as of Nov 19, 2026; other aggregators may differ. High and low targets show the range of estimates, not forecasts.
Previous notable changes for EW
Frequently asked questions about EW
Why did Edwards Lifesciences Corporation (EW) stock move?
Edwards Lifesciences Corporation (EW) rose 2.5% on November 9, 2026, closing at $104.71 versus $102.14 the prior session (close-to-close, from daily closes). Driven by continued positive momentum from its strong Q3 2026 results ($1.72B sales, $0.80 adjusted EPS beat), raised full-year guidance, and a wave of analyst price-target upgrades from UBS, JPMorgan, Citigroup, and Truist Financial. Volume was normal at 1.09x the historical average for this time of day. Source: defenseworld.net.
How much did EW stock fall?
EW lost 0.39% ($0.42) versus the prior close of $105.23, last trading at $104.82 on 0.0× average volume.
When is Edwards Lifesciences Corporation's next earnings date?
EW's next earnings report is estimated for 2027-02-09 — about 82 days away.
What is the analyst price target for EW?
The consensus analyst price target for EW is $108.70, about 3.7% above the current $104.82. Over the past 90 days, analysts recorded 1 upgrade, 14 maintains, and 0 downgrades.
How BestStocks tracks EW
This page is generated automatically by BestStocks' change-detection system after its price and volume cleared EW-specific materiality thresholds, triggering an evidence check. It draws on 20 tracked change events for EW, cross-checked against the data sources listed below. Price, volume, and market-capitalization figures are the live intraday quote as of November 19, 2026 and refresh as new information is detected; for companies with multiple share classes, market-cap figures can differ by data source. Analyst price targets and ratings are FMP consensus. This is an educational summary of what changed and why — not personalized investment advice.
